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1. Introduction 
Nocistatin (NST) and nociceptin / orphanin FQ (N/OFQ) are two neuropeptides that are 
derived from the same precursor prepronociceptin (PNOC), and have physiological roles in 
nociception [Okuda-Ashitaka et al., 1998; Martin et al., 1998; Meunier et al., 1995; 
Reinscheid et al., 1995]. Regarding its effect on the central nervous system, N/OFQ is 
considered to act as an important neuroendocrine regulator of female reproductive functions 
[Foradori et al., 2007]. The direct, peripheral actions of N/OFQ and NST have been sparsely 
investigated yet.  
In this project we intended to focus on the possible involvement of NST, another peptide 
derived from the same precursor protein as N/OFQ, in the regulation of uterine contractility in 
the rat. We also aimed to find evidence for the participation of N/OFQ and NST in the control 
of human myometrial activity at term, with a theoretical perspective to provide suggestions 
for future tocolytic therapy. 
 
2. Experiments on pregnant rats 
2.1. Animals 
The animals used in the experiments were treated in accordance with the European 
Communities Council Directives (86/609/ECC) and the Hungarian Act for the Protection of 
Animals in Research (XXVIII.tv.32.§). All experiments involving animal subjects were 
carried out with the approval of the Hungarian Ethical Committee for Animal Research 
(registration number: IV./01758-2/2008) and under the control of the ISO-9001:2008 Quality 
Management System. 
 
2.2. RT-PCR (Real-time reverse transcription polymerase chain reaction) studies 
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Rat uterine prepronociceptin (PNOC) mRNA expressions were determined on selected days 
of late pregnancy (days 18, 20 and 22) by RT-PCR.  The myometrial PNOC mRNA levels 
increased significantly as pregnancy progressed: the levels of PNOC mRNA/β-actin mRNA 
were lowest on day 18 of pregnancy. The relative expression of PNOC mRNA on day 20 was 
not different from that on day 18, but it was increased by day 22, the day of delivery. With 
this experiment, it was confirmed for the first time, that PNOC mRNA is expressed in the 
pregnant rat uterus. 
 
2.3. Radioimmunoassay (RIA) for NST in the rat uterus and plasma 
RIA experiments were not planned in the project protocol. However, later we presumed it was 
necessary, to be able justify the translation of PNOC mRNA to NST protein in the rat uterus 
as well (similarly as we did before in case of N/OFQ, [Klukovits et al. 2010]). The extraction 
of NST from uterus tissue was carried out by a validated method. The RIA experiments 
revealed that the myometrial NST levels were relatively low on pregnancy days 18 and 20, 
then elevated significantly by day 22, the day of delivery (Table 1). The plasma levels of 
NST did not change with the progression of pregnancy. Furthermore, we found that NST in 
pregnant rat uterus at term is about 10 times more abundant than N/OFQ [Klukovits et al. 
2010], so it seems that PNOC mRNA is translated mainly to NST, rather than to N/OFQ. 
 
Table 1. Tissue and plasma NST levels in 18,  20 and 22 day pregnant rats (n=6). 
 
Tissue  pg/100 mg uterine tissue ± S.E.M 
pg/ml plasma 
± S.E.M 
 
18 day pregnant   17.15±3.03 ns 11.52±1.62  ns 
20 day pregnant   13.95±1.82 ns 12.19±1.57  ns 
22 day pregnant   42.11±6.27 * 17.59±2.12  ns 
 
*p<0.05, ns: nonsignificant. Significances are expressed relative to the value of the previous tested day. 
 
As regards the higher spontaneous contractility during delivery, the elevation of NST levels in 
the myometrium at term appears rather contradictory, especially in the light of our results, 
assuming that NST has uterus relaxing effect. Nevertheless, it was also reported that NST 
inhibit hyperalgesia and allodynia, thus it has a regulatory role in pain signalling, which may 
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explain its functional importance during labour [Li et al. 2012; Minami et al. 1994a; Minami 
et al. 1994b; Taiwo et al. 1988]. 
 
2.4. In vitro contractility studies 
These experiments were the most numerous during the run of the project. They were 
performed by Anna Klukovits, Principal Investigator and Beáta Deák, a PhD student 
mentioned in the project proposal.  
In the isolated uterine rings from day-22 pregnant rats, rhythmic contractions were elicited 
with KCl, oxytocin (oxy) or with PGF2α (Figure 1). NST acted as an inhibitor of the uterine 
contractions, evoked by the above contracting agents. The most potent inhibitory effect of 
NST was found against KCl, therefore this agent was used in the further studies to investigate 
the possible mechanism of action of NST (Table 2).  
 
A 
 
 
 
 
 
 
B 
 
 
 
 
C 
 
Fig. 1. Representative online recordings of the inhibitory effects of nocistatin (NST) and nociceptin 
(PNOC) on pregnant uterine contractions in vitro. 
The contractions were elicited with 1 μM oxytocin (A) or with 1 μM prostaglandin F2 alpha (B) or with 25 mM 
KCl (C).  
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N/OFQ was able to potentiate the relaxant effect of NST, which was an interesting finding 
since NST counteracts the effects of N/OFQ relating to their actions in the central nervous 
system [Okuda-Ashitaka and Ito, 2000; Okuda-Ashitaka et al. 1998]. 
 
Table 2.  EC50 and maximum inhibitory values of nocistatin (NST) alone and in the presence of nociceptin 
(N/OFQ) on prostaglandin F2 (PGF2α) or KCl-stimulated contractions; and of NST with N/OFQ+NX on 
KCl-stimulated contractions in the 22-day-pregnant rat uterus in vitro (n=8). 
Substance EC50 ( × 10-10 M ± S.E.M.) Emax (% ± S.E.M.) 
NST (on PGF2α-evoked contraction) 10.05 ± 1.12  25.97 ± 3.15   
NST + N/OFQ 0.59 ± 0.13 * 33.98 ± 4.19 * 
NST (on KCl-evoked contraction) 194.1 ± 117.3  56.10 ± 4.82  
NST + N/OFQ 428.0 ± 250.8 ns 65.78 ± 9.42 *  
NST + N/OFQ + NX  58.2 ± 36.3  b 40.33 ± 2.73  a 
 
*p<0.05, ns: nonsignificant. Significances are expressed relative to NST alone. a: p<0.05, b: nonsignificant; significances are expressed 
relative to NST in the presence of N/OFQ.  
 
Since the receptor target of NST is still unknown, we examined the involvement of opioid 
receptors in the peripheral actions of NST. Naloxone (NX) decreased the contraction 
inhibiting effect of NST (Table 3), which was a surprise, opposing previous studies [Johnson 
and Connor, 2007; Fantin et al., 2007] that excluded the direct binding of NST to opioid 
receptors. Since it was demonstrated by others that NX induces inward Ca2+ currents [Kai et 
al., 2002], we wondered whether the inhibitory effect of NX on NST-induced uterus 
relaxation is mediated by the opening of inward rectifying Ca2+ channels. In Ca2+-poor 
environment, NX did not decrease the uterus-relaxant effect of NST (Table 3), suggesting 
that without an inward Ca2+ current, NX could not overcome the relaxing effect of NST.  
 
Hereby, we provided evidence that the site of interaction between NST and NX is rather the 
inward rectifying Ca2+ channels.  
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Table 3. EC50 and maximum inhibitory effects of nocistatin (NST) alone and in the presence of naloxone 
(NX) on KCl-stimulated uterine contractions in the 22-day-pregnant rat in vitro, either in standard Ca2+-
containing or in Ca2+-poor de Jongh solutions (n=6). 
Substance EC50 ( × 10-10 M ± S.E.M.) Emax (% ± S.E.M.) 
NST (1 mM Ca2+) 194.1 ± 117.3 a 56.10 ± 4.82  
NST + NX (1 mM Ca2+) 106.2 ± 48.8 ns; a 24.78 ± 3.08  ***
NST (0.5 mM Ca2+) 0.3 ± 0.1   47.21 ± 4.27  
NST + NX (0.5 mM Ca2+) 0.5 ± 0.2 ns 47.82 ± 4.85  ns
 
***p<0.001, ns: nonsignificant. The significances of the joint effect of NST + NX are expressed relative to NST alone in the same Ca2+-
containing de Jongh solution. a: p<0.05; significances are expressed relative to the same substance in a different Ca2+-containing de Jongh 
solution.  
 
Additional experiments were done in the presence of the KCa1.1  channel (Ca2+-dependent K+ 
channel)-selective blocker paxilline (PAX), against spontaneous uterine contractions in 
standard de Jongh buffer, in order to investigate the participation of the outward rectifying K+ 
channels in mediating the effects of NST. In the uterus, the plentiful KCa1.1 channels play an 
important role in decreasing depolarization, thereby relaxing the uterine smooth muscle. PAX 
inhibited the uterus-relaxant effect of NST (Emax decreased from 33% ± 3% to 11% ± 4%) as 
evidence that the Ca2+-dependent K+ channels play a role in the intracellular signalling of 
NST.  
 
The possible involvement of CGRP, a sensory neuropeptide, in the actions of NST was also 
tested on uterine tissue. The rationale for these experiments was that inflammatory mediators 
are known to play a role in the initiation of labour, yet some of them (e.g. calcitonin gene-
related peptide; CGRP) exhibit utero-relaxant activity among their various effects. Besides, 
pioid-like nociceptive peptides have been reported to release neurotransmitters, among them 
CGRP, from capsaicin-sensitive primary sensory neurons [Peiser et al., 2000; Helyes et al., 
1997]. Although the uterus undergoes a gestation induced denervation, the process mainly 
affects adrenergic and not sensory units, leaving CGRP-containing nerves mainly intact 
[Klukovits A et al., 2004]. We investigated the effect of NST either on capsaicin-induced 
CGRP-depleted uterus samples or on CGRP-reloaded uterus samples (Table 4). 
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Table 4. EC50 and maximum inhibitory effects of nocistatin (NST) after preincubation with capsaicin (1 
µM), with the solvent of capsaicin (control) and with capsaicin (1 µM) and CGRP (0.1 µM) (n=6). 
Substance EC50 ( × 10-11 M ± S.E.M.) Emax (% ± S.E.M.) 
NST control 73.7 ± 47.3  48.72 ± 7.18  
NST preincubated with capsaicin not converged  ns 6.14 ± 4.79 ** 
NST preincubated with capsaicin and CGRP 160.6 ± 57.3  ns 35.05 ± 7.38  ** 
 
 **p<0.01, ns: nonsignificant. Significances after preincubation with capsaicin are expressed relative to NST alone, and significances after 
preincubation with capsaicin and CGRP are expressed relative to preincubation with capsaicin alone. 
 
Neuropeptide depletion from the capsaicin-sensitive primary afferents was induced with 
capsaicin, after which the maximum uterus-relaxant effect of NST was decreased. When the 
neuropeptide depletion was followed by the addition of CGRP, the maximum uterus-relaxant 
effect of NST was higher than after incubation with capsaicin. Therefore, the re-addition of 
CGRP restored the relaxant effect of NST as compared with the control. We assume that 
CGRP is an important factor in the uterus-relaxant effect of NST. NST, similarly to opioid 
peptides and N/OFQ, may promote the release of neuropeptides from sensory nerves [Moran 
et al., 2000].  
 
2.4. Measurement of uterine cAMP accumulation by enzyme immunoassay (EIA) 
For further investigation of the mechanism by which NST inhibits uterine contractions, the 
effect of NST on uterine cAMP accumulation was measured by EIA. We detected moderate 
elevation of cAMP levels in the presence of NST, similarly as in the case of N/OFQ. In the 
presence of N/OFQ with NST, a further cAMP level elevation was found, which can be 
explained by the mutual cAMP-accumulating effects of N/OFQ and NST-induced CGRP 
liberation [Klukovits et al., 2010]. In correlation with the contractility studies, NX decreased 
the cAMP levels elevated by NST, which suggests that NX interferes with NST at the level of 
G-protein activation, too. 
 
3. Experiments on isolated human uterus specimens 
3.1. Human subjects 
Biopsy specimens of human myometrial tissue were obtained from the Department of 
Obstetrics and Gynecology, University of Szeged, with the help of Zsolt Kormányos, MD, 
PhD, as it was indicated in the proposal.  Uterine strip excisions were made at cesarean 
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sections, with the approval of The Ethical Committee of Albert Szent-Györgyi Clinical Center 
(registration number: 114/2009); and with the uninfluenced informed consent from the 
pregnant women. Uterine specimens were grouped as (1) at full term pregnancy (37-41 weeks 
of gestation) and (2) at preterm birth (33-36 weeks). We note here, that preterm deliveries 
which end up with caesarean sections – and not spontaneous labour - were quite rare at our 
University Clinic. During the first (and only) year of the project, we could perform the RT-
PCR studies and the basic in vitro contractility studies. 
 
3.2. RT-PCR studies 
The myometrial PNOC mRNA levels were significantly higher in preterm uterine samples as 
compared with samples from full term pregnancy.  
 
3.3. In vitro contractility studies 
In the isolated uterine rings, rhythmic contractions were elicited with 10-8 M oxy. The effects 
of N/OFQ and NST on the uterine contractions were tested in the concentration range 10-12 – 
10-6 M, in a non-cumulative manner. In the full-term human myometrium N/OFQ alone 
decreased uterine contractility concentration-dependently, which was further increased by 
NST. NST alone also showed uterus relaxant effect, which was not different in the presence 
of N/OFQ (Table 5). In the uterus specimens from preterm birth N/OFQ alone decreased the 
oxy induced uterine contractions, which effect was further increased by NST, providing the 
most pronounced inhibitory effect on the human samples. NST alone also showed uterus 
relaxant effect, which was not altered by N/OFQ.  
 
Table 5. Maximum inhibitory values of nociceptin (N/OFQ) alone and in the presence of nocistatin (NST) 
and of NST alone and in the presence of N/OFQ on oxytocin-stimulated uterine contractions from term 
and preterm human pregnancy in vitro.  
 Emax (% ± S.E.M.)  Emax (% ± S.E.M.) 
Term-pregnant uterus   Preterm-pregnant uterus   
N/OFQ 29.07 ± 1.61   N/OFQ 27.51 ± 4.31  
N/OFQ + NST 43.79 ± 3.61  *** N/OFQ + NST 56.29 ± 4.94 *** 
NST  42.01 ± 9.48  NST 35.55 ± 6.58  
NST + N/OFQ 38.24 ± 7.05 ns  NST + N/OFQ 37.92 ± 7.40 ns 
 
*** p<0.001; significances are expressed relative to N/OFQ. ns: non-significant; significances are expressed 
relative to NST. 
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As we have previously shown the CGRP-liberating effect of NST as well as the cAMP-
accumulating effect of N/OFQ and NST in the pregnant rat uterus [Klukovits et al., 2010; 
Deák et al. unpublished], these results may also explain the uterus-relaxant effect of N/OFQ 
and NST and their intracellular signalling in the human uterus. We can also conclude from the 
human in vitro experiments that NST administration must precede the administration of 
N/OFQ, in the aim to enhance the common uterus-relaxant effect. NST stimulates CGRP 
liberation, which effect is weak compared to the more prominent potassium channel opening 
effect caused by N/OFQ. When N/OFQ is administered first, the CGRP elevation cannot 
exceed the effect of potassium channel opening caused by standard-dose of N/OFQ.  
4. Conclusions and remarks 
Investigation of the actions of the nociceptive peptides NST and N/OFQ has provided 
substantial new information relating to the mediation of uterine contractions at term, either 
physiological or pathological. By completing the tasks of the project, we contributed to the 
current knowledge on the peripheral actions of N/OFQ and NST, which has mostly covered 
their role in pain processing by far.  
Finding the mRNA for PNOC in the rat and human uterus confirmed a local regulatory role 
for NST and N/OFQ in uterine functions. We also justified in the rat uterus that PNOC 
mRNA is translated to both N/OFQ and NST, the latter being more abundant at term. 
Unfortunately, due to the restricted time of the project, we were not able to show evidence for 
the existence of specific binding sites for NST in the uterus, which would have been a 
significant step towards the identification of NST receptors.  
Upon the results of the in vitro contractility assays on the pregnant rat uterus, we provided 
evidence that NST alone and also in combination with N/OFQ exert a relaxant effect. This 
mechanism was mediated in part by KCa1.1 channels (Ca2+-dependent K+ channels) and 
consequent hyperpolarization, and by the release of the sensory neuropeptide CGRP. The 
increased cAMP-accumulation by NST probably plays a minor role in its contraction 
inhibiting effect. We also proved the efficacy of N/OFQ and NST on human specimens (at 
term and preterm labour) to decrease uterine contractions in vitro. If N/OFQ and NST are co-
administered, NST should be added first in order to maximize the relaxant effect.  
Further experiments on human tissue are necessary to allow conclusions on the relevance of 
the present findings as concerns human disease. Understanding this complex signaling 
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pathway, however, may provide an opportunity for the development of novel treatments for 
the inhibition of uterine contractions arising before the term of pregnancy. 
The results of the project PD-100868 are going to be published in the near future, in 2 
manuscripts:  
Deák BH, Klukovits A, Tekes K, Ducza E, Falkay G, Gáspár R. Nocistatin inhibits pregnant rat uterine 
contractions in vitro: roles of calcitonin gene-related peptide and calcium-dependent potassium channel. Under 
major revision at European Journal of Pharmacology; manuscript number: EJP-37241 
Deák BH, Klukovits A, Tekes K, Ducza E, Kormányos Z, Gáspár R. Uterus-relaxing effect of nociceptin and 
nocistatin: studies on preterm and term-pregnant human myometrium in vitro. Manuscript written, to be 
published in Reproductive System and Sexual Disorders. 
On behalf of my co-workers and assistants, who helped me to accomplish this project, I 
am deeply grateful for the financial support provided by OTKA. I would also like to 
render thanks for their understanding and letting me finish the project earlier than it 
was supposed to.  
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